Compare Illumina, Inc. (ILMN) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs OneSpan Inc — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while OneSpan Inc trades at $15.27 (market cap $575.37M). The key difference: Illumina, Inc. is far larger — about 48.6× OneSpan Inc's market cap, and OneSpan Inc pays a 3.35% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | OSPN | |
|---|---|---|
Market Cap | $27.94B | $575.37M |
Sector | Health | Technology |
52-Week High | $194.33 | $16.32 |
52-Week Low | $91.00 | $10.15 |
Enterprise Value | $29.33B | $533.57M |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
OneSpan (OSPN) trades at $15.51, showing modest daily gains of 0.26% with strong technical momentum indicated by bullish moving averages. The company demonstrates robust profitability with a 28.47% net income margin and consistent earnings beats in recent quarters. Recent corporate developments include a $0.13 dividend payment and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents attractive valuation metrics with a P/E of 8.55 and strong analyst support (66.7% buy ratings), though current price exceeds the $13.50 consensus target. Key risks include negative cash flow trends and competitive pressures in the cybersecurity sector. Earnings growth remains the primary catalyst for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
